Navigation Links
GlycoMeds Discovery Yields Early Warning Test for Cancer

PHOENIX, Feb. 4 /PRNewswire/ -- Cancer is the second leading cause of death with over 6 million new cases worldwide each year. In the U.S. alone, one million new cases of cancer are diagnosed annually, and half a million Americans lose their battle with the disease every year. Now, following years of research, GlycoMeds ( has released the first early detection system for whole-body cancers.

What was needed was a way to detect it in the early stages when it's easiest to treat. The medical establishment has long sought just such a tool -- a reliable, simple test that catches cancer in its early stages. While a few companies have designed tests for specific cancers, those tests require the cancer to be present. What's more, these tests are limited to only a few specific types of cancer.

In contrast, the GlycoMeds patent-pending Cancer Test ( is a broad-scope test that detects conditions within the body that allow cancer cell growth prior to cancer cells being active. Employing a test process that produces consistent measurements of the chemical composition of a person's saliva, GlycoMeds' Cancer Test Kit is an inexpensive, at-home test that can alert the user to the presence of conditions within their body that are conducive to the growth of 74% of all cancers (including breast, lung, kidney, colon, liver, bone and brain cancer). The Cancer Test Kit does not measure pH.

"The new Cancer Test is not keyed for any specific cancer," explained Dr. Roger Brown, CEO of GlycoMeds. "The test is more sensitive to whole-body type of cancers rather than small, localized malignant tumors which don't generally disrupt the body's entire system."

The GlycoMeds Cancer Test works because most cancer cells live in a narrow pH range within the body. As long as the body's system pH is outside that range, most cancer cells cannot survive. The GlycoMeds test measures the changes in a person's fluidic system once a day for three days, averages those changes, and compares them to the changes a healthy person's fluidic system would undergo. The measurement is then equated to a condition level on a scale of 0 to 7, where 0 is healthy -- no conditions conducive to the growth of whole-body cancer cells -- and 7 has a prognosis of death.

If the level number reveals an active possibility of cancer (levels 4, 5 or 6), the person taking the test is advised to make an appointment with his or her doctor for further evaluation. But if the test shows cancer is not imminent (levels 1, 2 or 3), the person taking the test can take corrective action to bring his or her system back to normal, thus inhibiting cancer cell growth.

GlycoMeds is now seeking a partner to license and market their Cancer Test Kit, which has not yet been presented to the FDA for comment. To learn more, visit


    Roger Brown, Ph.D.

This release was issued through eReleases(TM). For more information, visit

SOURCE GlycoMeds
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... Using a combination ... prediabetes in American children and adults, according to a new study by researchers at ... of Prediabetes in Children and Adults: Using Combinations of Blood Glucose Tests ,” published ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Association of Poison Control Centers’ National Poison Data System (NPDS) reveals that in ... managed almost 3 million cases, over two million of which were human exposure ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (ASI) as their exclusive channel partner for the Nutraceutical Specialties products into oral ... the US, effective immediately. , “We are pleased to announce our expanded ...
(Date:11/30/2015)... Chicago, Ill. (PRWEB) , ... November 30, 2015 ... ... and Decision Support Solutions, announced at the Radiology Society of North America (RSNA) ... bookings have seen over 60% growth from 2014. Throughout 2015, the company ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Kreithen”), one of the leading plastic surgery practices in Florida, is proud to ... to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BOSTON , Nov. 30, 2015  Kevin ... of Sensium Healthcare, a global pioneer in wireless ... Boston, MA , Mr. Smith ... of Sensium,s global commercial strategy.  He will also ... universities, to build clinical evidence for SensiumVitals, the ...
(Date:11/30/2015)... , Nov. 30, 2015  The fee-for-service ... in U.S. medical imaging is on its ... accountable care payer-provider contracts are set to ... their wake, alter provider-vendor relationships. The shift ... push forward new purchasing frameworks in the ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
Breaking Medicine Technology: